ArticleMolecular and cellular biochemistry2026
FOXP1-transcriptionally regulated AEG-1 enhances tumor cell stemness to promote hepatocellular carcinoma radioresistance.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Radiotherapy is the standard adjuvant treatment for hepatocellular carcinoma (HCC). Cancer stem cells (CSCs) have been identified as the primary factor contributing to radiation resistance. Astrocyte elevated gene-1 (AEG-1) could regulate β-catenin signaling to maintain tumor stem-like stemness and self-renewal. This study aims to explore the role and mechanism of AEG-1 in the radioresistance of HCC. The mRNA levels of AEG-1 and FOXP1 were determined using RT-qPCR. AEG-1, FOXP1, Oct4, CD133, Nanog, β-catenin, and c-Myc protein levels were detected using western blot. The radiosensitivity of HCC cells was assessed using cell colony formation assay, γ-H2AX immunofluorescence, and flow cytometry. The CSC characteristics of cells were examined using sphere formation assay. The biological role of AEG-1 on HCC tumor growth and radiation resistance was examined by the mouse xenograft tumor model. Correlation between AEG-1 and FOXP1 in HCC patients was analyzed using Pearson correlation analysis. Binding between FOXP1 and AEG-1 promoter was predicted by JASPAR and verified by ChIP, the electrophoretic mobility shift assays (EMSA), and dual-luciferase reporter assays. AEG-1 was highly expressed in HCC patients, and positively associated with FOXP1 expression. Moreover, AEG-1 knockdown could enhance the radiosensitivity of HCC cells by promoting ionizing radiation (IR)-DNA damage and apoptosis in vitro. AEG-1 mediated radiation resistance by maintaining HCC tumor stem cell properties. In vivo investigation revealed that AEG-1 silencing repressed HCC tumor growth and increased radiosensitivity. Mechanistically, FOXP1 was a transcription factor of AEG-1 that promoted AEG-1 transcription by binding to its promoter region. FOXP1 promoted the Wnt/β-catenin pathway by regulating AEG-1. Overall, overexpressing FOXP1 drives stem cell properties and radioresistance of HCC cells by promoting AEG-1-mediated Wnt/β-catenin pathway, providing a promising therapeutic target for enhancing radiotherapy efficacy.
Indexed as
Identifiers
41152549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.